Discover and read the best of Twitter Threads about #ada2021

Most recents (4)

Yes it's the @GoggleDocs as we continue our #takeover of the @cardiomet_CE account.

Reporting some of the things that interested us in the recent #EASD2021

Please check out our previous mini-tweetorials.

@EASDnews @EASDelearning @ADA_DiabetesPro
Thus far we have covered...

▶️ Latest data on tirzepatide (GIP/GLP-1 dual agonist)✅
▶️ "Triple G" - a new GIP/GLP-1/Glucagon agonist✅
▶️ Remission in non-obese #type2diabetes

Next up is "what's next after metformin?" - what the GRADE & TriMaster Studies add
Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

📍Presented an update at the #EASD2021 , although little changed from the #ADA2021 presentation.

Please check out one of our own @GoggleDocs posts at the time

Read 13 tweets
1/6
#ADA2021
Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

Q. What next after metformin?

MET plus:
✅GLP-1ra (liraglutide)
✅Insulin(glargine)
✅SU (glimepiride)
✅DPP4i (sitagliptin)

But
😱 No SGLT2i
😱 No TZD

care.diabetesjournals.org/content/36/8/2…
2/6
Mean baseline characteristics

57 yr old
♀️36%
66%👴🏻, 20%👴🏿
BMI 34
HbA1c 7.5%
Duration of diabetes 4.2 yr

⚠️🇺🇸 only study
⚠️only 3.6% from 'Asian' descent
⚠️ So not representative to non-🇺🇸 #type2diabetes

care.diabetesjournals.org/content/42/11/…
3/6
Summary of glycaemic outcomes

🥳GLP-1ra & Basal Insulin did best

💩DPP4i did worse. In particular if baseline HbA1c>7.8%

Bottom line - I don't think DPP-4i is a good option if HbA1c >7.8% (62mmol/mol)

📷courtesy of Prof. Matthews
Read 6 tweets
AMPLITUDE-O Trial
1/5
Cardiovascular outcome trial for Efpeglenatide an investigational once weekly Exendin-4 based GLP-1ra.

What are the unanswered questions
Do Exendin-based GLP-1a ⤵️ MACE❓
Do GLP-1ra ⤵️ MACE in people taking SGLT2i❓
Does GLP-1ra ⤵️ renal decline❓

#ADA2021
2/5
Main results

Efpeglenatide
⤵️3-point MACE by 27%
⤵️expanded MACE by 21%
⤵️Renal composite by 32%
⤵️MACE or non-CV death by 27%

Best data yet to suggest adding GLP-1ra to SGLT2i ⤵️MACE

@DLBHATTMD
3/5
Renal outcomes

Efpeglenatide
⤵️Renal composite
⤵️Albuminuria
⤵️eGFR slope❗️
Read 6 tweets
#ADA2021
1/6
✅Real world data from a 🇩🇪register of patients with ♂️#hypogonadism & #type2diabetes over 12 years!

❗️ ♂️ hypogonadism is common in T2D (≈ 50%)

⚠️@Bayer presented
⚠️ other data shown ⤴️ MACE
amjmed.com/article/S0002-…

So what did they find?
2/6

Baseline Characteristics.

🤔As you can see two very different cohorts of patients.

⚠️ High risk of unresolved bias
3/6

Changes in testosterone and glycaemic markers over time.

Testosterone therapy assoc with

⤴️ Testosterone
⤵️ HbA1c
Read 6 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!